FATE 4.05 Fate Therapeutics Inc $FATE Hit a 52 week low of 3.91 Closing the day 11/07/14 at 4.05 -0.41 -9.19% With a day low of 3.91 and a total volume of 25,050.
FATE Recent Posts: http://investorshangout.com/Fate-Therapeutics...ATE-90047/
FATE Fate Therapeutics Inc Recent Headline News
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2014 Financial Results on November 11, 2014
GlobeNewswire - Tue Nov 04, 3:01PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Tuesday, November 11, 2014, at 5:00 p.m. EST to report its third quarter 2014 financial results and to provide a corporate update.
FATE: 4.05 (-0.41)
Fate Therapeutics to Present at Nomura Biotechnology Conference
GlobeNewswire - Thu Oct 30, 6:09AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer will discuss the company's programs at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 11:30am EST in Boston, MA.
FATE: 4.05 (-0.41)
Fate Therapeutics (FATE) Crumbles: Stock Tumbles by 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:50AM CDT
Fate Therapeutics has been witnessing a flat trend in its current year estimates and its share price has been falling for past 1 month
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), FATE: 4.05 (-0.41), ILMN: 186.35 (-3.52)
Fate Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 3:01PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer will present an overview of the company's programs at the Rodman & Renshaw 16 Annual Global Investment Conference at New York Palace Hotel on Tuesday, September 9, 2014 at 2:30pm EDT in New York, NY.
FATE: 4.05 (-0.41)
Fate Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 12, 4:41PM CDT
First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment
FATE: 4.05 (-0.41)
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2014 Financial Results on August 12, 2014
GlobeNewswire - Tue Aug 05, 6:07AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 12, 2014, at 5:00 p.m. EDT to report its second quarter 2014 financial results and to provide a corporate update.
FATE: 4.05 (-0.41)
Fate Therapeutics Secures Up to $20 Million in Debt Financing
GlobeNewswire - Thu Jul 31, 3:01PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has completed a long-term debt financing of up to $20 million with Silicon Valley Bank. The Company has drawn down $10 million, at a fixed interest rate of 6.9%, under the first tranche of the debt facility.
FATE: 4.05 (-0.41)
Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders
GlobeNewswire - Tue Jul 29, 3:01PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for the clinical development of PROHEMA(R) in pediatric patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of inherited metabolic disorders (IMDs). The FDA's clearance of the IND allows the Company to begin expanding its clinical investigation of PROHEMA into rare, non-malignant disorders. The Company plans to initiate enrollment of the "PROVIDE" trial (PROHEMA eValuation for the treatment of Inherited metabolic DisordErs) in pediatric patients with IMDs in the fourth quarter of 2014.
FATE: 4.05 (-0.41)
Hearing Disorders - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7w63tx/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Adherex Technologies - Quark Pharmaceuticals - Novartis - Living Cell Technologies - Fate Therapeutics - Sound Pharmaceuticals - Pharmicell - Otologic Pharmaceutics - UniQure - AudioCure For more information visit http://www.researchandmarkets.com/research/7w..._disorders
FATE: 4.05 (-0.41), NVS: 91.76 (-0.27)
Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders
GlobeNewswire - Mon Jun 30, 3:09PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the clinical development of PROHEMA in pediatric patients with inherited metabolic disorders undergoing hematopoietic stem cell transplantation (HSCT). Pending FDA review of the IND application, the Company plans to initiate a Phase 1b clinical trial in pediatric patients who have inherited metabolic disorders where enzyme replacement therapy is not a viable treatment option, including certain patients with central nervous system involvement.
FATE: 4.05 (-0.41)
Fate Therapeutics (FATE) Falls: Stock Goes Down 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:37AM CDT
Fate Therapeutics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
FATE: 4.05 (-0.41), GILD: 106.45 (-0.49), ANIP: 46.00 (+1.21), ALKS: 51.00 (-0.03)
Fate Reports In-Line Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:28PM CDT
Share price of Fate Therapeutics (FATE) gained 10.3% after the company released fourth quarter earnings but lost 4.0% in the next trading session. Overall, shares gained 6.15% following the fourth quarter results.
FATE: 4.05 (-0.41), GILD: 106.45 (-0.49), ALXN: 193.81 (+0.67)
Fate Therapeutics adds Dr Robert S. Epstein to board
M2 - Tue Mar 18, 5:41AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) reported on Monday the election of Dr Robert S. Epstein, MD to its board of directors.
FATE: 4.05 (-0.41)
Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 17, 3:01PM CDT
Phase 2 PUMA Study of PROHEMA(R) Initiated - Interim Data Expected in 2H14
FATE: 4.05 (-0.41)
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
FATE: 4.05 (-0.41), AVEO: 0.89 (unch), ILMN: 186.35 (-3.52)
Fate Therapeutics' Prohema in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:50AM CDT
Fate Therapeutics' Prohema enters phase II study
FATE: 4.05 (-0.41), BIIB: 320.75 (-2.72), GILD: 106.45 (-0.49), ALXN: 193.81 (+0.67)
Fate Therapeutics enrolls first patient in Phase 2 clinical trial of PROHEMA under PUMA study for treating hematologic malignancies
M2 - Thu Mar 13, 4:25AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) disclosed on Wednesday the admission of the first patient in its "PUMA" study under its Phase 2 clinical trial of PROHEMA in patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies.
FATE: 4.05 (-0.41)
Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies
GlobeNewswire - Wed Mar 12, 6:01AM CDT
First Patient Enrolled in PUMA Study
FATE: 4.05 (-0.41)
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014
GlobeNewswire - Tue Mar 11, 6:02AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Monday, March 17, 2014, at 5:00 p.m. EDT to report its fourth quarter and full year 2013 financial results and provide a corporate update.
FATE: 4.05 (-0.41)
Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
GlobeNewswire - Thu Mar 06, 6:09AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the publication of an article in the journal Stem Cell Reports by Fate scientists demonstrating high-throughput derivation of human induced pluripotent stem cells (hiPSCs) that exhibit characteristics necessary for therapeutic application. The publication describes the use of the Company's hiPSC platform, consisting of stage-specific cell culture systems, to enable rapid, parallel derivation of hiPSC clones and their subsequent expansion as transgene-free, single cells in culture. The Company's proprietary combinations of small molecule modulators, which include ROCK, GSK3 and MEK pathway inhibitors, used in the culture systems were found to be critical in promoting characteristics of the ground state of pluripotency including pluripotent culture stability, homogeneity and survival.
FATE: 4.05 (-0.41)
FATE Recent Posts: http://investorshangout.com/Fate-Therapeutics...ATE-90047/
FATE Fate Therapeutics Inc Recent Headline News
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2014 Financial Results on November 11, 2014
GlobeNewswire - Tue Nov 04, 3:01PM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Tuesday, November 11, 2014, at 5:00 p.m. EST to report its third quarter 2014 financial results and to provide a corporate update.
FATE: 4.05 (-0.41)
Fate Therapeutics to Present at Nomura Biotechnology Conference
GlobeNewswire - Thu Oct 30, 6:09AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer will discuss the company's programs at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 11:30am EST in Boston, MA.
FATE: 4.05 (-0.41)
Fate Therapeutics (FATE) Crumbles: Stock Tumbles by 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:50AM CDT
Fate Therapeutics has been witnessing a flat trend in its current year estimates and its share price has been falling for past 1 month
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), FATE: 4.05 (-0.41), ILMN: 186.35 (-3.52)
Fate Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 3:01PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer will present an overview of the company's programs at the Rodman & Renshaw 16 Annual Global Investment Conference at New York Palace Hotel on Tuesday, September 9, 2014 at 2:30pm EDT in New York, NY.
FATE: 4.05 (-0.41)
Fate Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 12, 4:41PM CDT
First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment
FATE: 4.05 (-0.41)
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2014 Financial Results on August 12, 2014
GlobeNewswire - Tue Aug 05, 6:07AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 12, 2014, at 5:00 p.m. EDT to report its second quarter 2014 financial results and to provide a corporate update.
FATE: 4.05 (-0.41)
Fate Therapeutics Secures Up to $20 Million in Debt Financing
GlobeNewswire - Thu Jul 31, 3:01PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has completed a long-term debt financing of up to $20 million with Silicon Valley Bank. The Company has drawn down $10 million, at a fixed interest rate of 6.9%, under the first tranche of the debt facility.
FATE: 4.05 (-0.41)
Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders
GlobeNewswire - Tue Jul 29, 3:01PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for the clinical development of PROHEMA(R) in pediatric patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of inherited metabolic disorders (IMDs). The FDA's clearance of the IND allows the Company to begin expanding its clinical investigation of PROHEMA into rare, non-malignant disorders. The Company plans to initiate enrollment of the "PROVIDE" trial (PROHEMA eValuation for the treatment of Inherited metabolic DisordErs) in pediatric patients with IMDs in the fourth quarter of 2014.
FATE: 4.05 (-0.41)
Hearing Disorders - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7w63tx/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Adherex Technologies - Quark Pharmaceuticals - Novartis - Living Cell Technologies - Fate Therapeutics - Sound Pharmaceuticals - Pharmicell - Otologic Pharmaceutics - UniQure - AudioCure For more information visit http://www.researchandmarkets.com/research/7w..._disorders
FATE: 4.05 (-0.41), NVS: 91.76 (-0.27)
Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders
GlobeNewswire - Mon Jun 30, 3:09PM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the clinical development of PROHEMA in pediatric patients with inherited metabolic disorders undergoing hematopoietic stem cell transplantation (HSCT). Pending FDA review of the IND application, the Company plans to initiate a Phase 1b clinical trial in pediatric patients who have inherited metabolic disorders where enzyme replacement therapy is not a viable treatment option, including certain patients with central nervous system involvement.
FATE: 4.05 (-0.41)
Fate Therapeutics (FATE) Falls: Stock Goes Down 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:37AM CDT
Fate Therapeutics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
FATE: 4.05 (-0.41), GILD: 106.45 (-0.49), ANIP: 46.00 (+1.21), ALKS: 51.00 (-0.03)
Fate Reports In-Line Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:28PM CDT
Share price of Fate Therapeutics (FATE) gained 10.3% after the company released fourth quarter earnings but lost 4.0% in the next trading session. Overall, shares gained 6.15% following the fourth quarter results.
FATE: 4.05 (-0.41), GILD: 106.45 (-0.49), ALXN: 193.81 (+0.67)
Fate Therapeutics adds Dr Robert S. Epstein to board
M2 - Tue Mar 18, 5:41AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) reported on Monday the election of Dr Robert S. Epstein, MD to its board of directors.
FATE: 4.05 (-0.41)
Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 17, 3:01PM CDT
Phase 2 PUMA Study of PROHEMA(R) Initiated - Interim Data Expected in 2H14
FATE: 4.05 (-0.41)
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
FATE: 4.05 (-0.41), AVEO: 0.89 (unch), ILMN: 186.35 (-3.52)
Fate Therapeutics' Prohema in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:50AM CDT
Fate Therapeutics' Prohema enters phase II study
FATE: 4.05 (-0.41), BIIB: 320.75 (-2.72), GILD: 106.45 (-0.49), ALXN: 193.81 (+0.67)
Fate Therapeutics enrolls first patient in Phase 2 clinical trial of PROHEMA under PUMA study for treating hematologic malignancies
M2 - Thu Mar 13, 4:25AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) disclosed on Wednesday the admission of the first patient in its "PUMA" study under its Phase 2 clinical trial of PROHEMA in patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies.
FATE: 4.05 (-0.41)
Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies
GlobeNewswire - Wed Mar 12, 6:01AM CDT
First Patient Enrolled in PUMA Study
FATE: 4.05 (-0.41)
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014
GlobeNewswire - Tue Mar 11, 6:02AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Monday, March 17, 2014, at 5:00 p.m. EDT to report its fourth quarter and full year 2013 financial results and provide a corporate update.
FATE: 4.05 (-0.41)
Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
GlobeNewswire - Thu Mar 06, 6:09AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the publication of an article in the journal Stem Cell Reports by Fate scientists demonstrating high-throughput derivation of human induced pluripotent stem cells (hiPSCs) that exhibit characteristics necessary for therapeutic application. The publication describes the use of the Company's hiPSC platform, consisting of stage-specific cell culture systems, to enable rapid, parallel derivation of hiPSC clones and their subsequent expansion as transgene-free, single cells in culture. The Company's proprietary combinations of small molecule modulators, which include ROCK, GSK3 and MEK pathway inhibitors, used in the culture systems were found to be critical in promoting characteristics of the ground state of pluripotency including pluripotent culture stability, homogeneity and survival.
FATE: 4.05 (-0.41)
